Does this look like a real woman? AI Vogue model raises concerns about beauty standards
In August's print edition of Vogue, a Guess advert features a flawless blonde model showing off a striped maxi dress and a floral playsuit from the brand's summer collection.
In small print in one corner, the ad reveals that she was created using AI.
While Vogue says the AI model was not an editorial decision, it is the first time an AI-generated person has featured in the magazine.
The advert has been met with controversy and raises questions about what this means for real models who have fought for greater diversity, and for consumers - particularly young people - already struggling with unrealistic beauty standards.
Seraphinne Vallora is the company behind Guess's controversial advert.
Its founders, Valentina Gonzalez and Andreea Petrescu, tell the BBC they were approached by Guess's co-founder, Paul Marciano, on Instagram and were asked to create an AI model as part of the brand's summer campaign.
"We created 10 draft models for him and he selected one brunette woman and one blonde that we went ahead and developed further," Gonzalez says.
She explains there's often a misconception that AI image generation is simple, saying it is actually a complex process.
The company has five employees who create AI models, and it can take up to a month from idea inception to the completed product. The pair say they charge anywhere up to low six figures for a client like Guess.
'Disheartening'
But Felicity Hayward, a plus-size model who has been in the industry for more than a decade, says using AI models in fashion campaigns "feels lazy and cheap".
"Either Guess is doing this to create a talking point and get free publicity or they want to cut costs and don't think about the implications of that."
She describes Vogue's decision to include the advert as "very disheartening and quite scary", and worries it could undermine years of work towards more diversity in the industry.
The fashion world was making real progress to be more inclusive in the 2010s - the decade saw Valentina Sampaio become the first openly trans model to walk for Victoria's Secret, Halima Aden was the first hijab-wearing model in global campaigns, and brands like Savage x Fenty featured plus-size models on the runway.
But in recent years, Hayward believes, the industry has slipped backwards because "these people are just not getting booked any more".
And the use of AI models is "another kick in the teeth, and one that will disproportionately affect plus-size models", she warns.
Gonzalez and Petrescu are adamant they don't reinforce narrow beauty standards.
"We don't create unattainable looks - actually the AI model for Guess looks quite realistic," Petrescu says. "Ultimately, all adverts are created to look perfect and usually have supermodels in, so what we are doing is no different."
The pair admit the AI images on their company's Instagram page are lacking in diversity and promote unrealistic beauty standards. They say they have tried to be more inclusive, but it's the users who don't engage much with those posts.
"We've posted AI images of women with different skin tones, but people do not respond to them - we don't get any traction or likes," Gonzalez tells the BBC.
"At the end of the day, we are a business and use images on Instagram that will create a conversation and bring us clients."
The company is yet to experiment with creating plus-size women, claiming "the technology is not advanced enough for that".
An ad campaign by Dove in 2024 was designed to highlight the biases in AI. In the advert, an image generator is asked to create the most beautiful woman in the world and produces virtually indistinguishable women who are young, thin and white, with blonde hair and blue eyes. The images generated look similar to the Guess AI model.
Hayward worries that seeing these unattainable images could have an impact on people's mental health and negatively affect their body image.
Concern around unrealistic beauty standards and the damaging effects they can have is nothing new. But unlike traditional airbrushing, which at least began with a real person, these AI models are digitally created to look perfect, free from human flaws, inconsistencies or uniqueness.
While some high-profile figures such as Ashley Graham, Jameela Jamil and Bella Thorne have spoken out against image editing and refuse to have their pictures Photoshopped, the use of AI sidesteps such conversations entirely.
Vogue's decision to include an AI-generated advert has caused a stir on social media, with one user on X writing: "Wow! As if the beauty expectations weren't unrealistic enough, here comes AI to make them impossible. Even models can't compete."
Vanessa Longley, CEO of eating disorder charity Beat, tells the BBC the advert is "worrying".
"If people are exposed to images of unrealistic bodies, it can affect their thoughts about their own body, and poor body image increases the risk of developing an eating disorder," she says.
'Exceptionally problematic'
Adding to the issue is the lack of transparency - it is not a legal requirement to label AI-generated content in the UK.
While Guess labelled its advert as AI-generated, the disclaimer is small and subtle. Readers may overlook it and, at a glance, the image appears entirely lifelike.
Sinead Bovell, a former model and now tech entrepreneur, wrote an article for Vogue five years ago about the risks of AI replacing modelling.
She tells the BBC that not labelling AI content clearly is "exceptionally problematic" because it could have a detrimental impact on people's mental health.
"Beauty standards are already being influenced by AI. There are young girls getting plastic surgery to look like a face in a filter – and now we see people who are entirely artificial," she says.
Aside from the impact AI models could have on a consumer, especially if unlabelled, what about the impact of this technology on those working in the fashion industry?
Sara Ziff is a former model and founder of Model Alliance, an organisation that aims to advance workers' rights in the fashion industry.
She says Guess's AI campaign is "less about innovation and more about desperation and need to cut costs".
More broadly, the former model thinks AI in the fashion industry is not inherently exploitative, but can often come at the expense of the people who bring it to life because there are many more staff involved in a photoshoot than just the model and the photographer.
"AI can positively impact the industry, but there need to be meaningful protections for workers," she explains.
'Supplement not replace'
Seraphinne Vallora rejects the notion that it is putting people out of work, and says its pioneering technology "is supplementary and not meant to replace models".
"We're offering companies another choice in how they market a product," Petrescu explains.
The pair add that they have created jobs with their company, and part of the process of creating AI models requires them to hire a real model and photographer to see how the product looks on a person in real life.
However, its website lists one of the benefits of working with them as being cost-efficient because it "eliminates the need for expensive set-ups, MUA artists, venue rentals, stage setting, photographers, travel expenses, hiring models".
Vogue has come under fire for including the advert in its print edition, with one person on X saying the fashion magazine had "lost credibility".
Bovell says the magazine is "seen as the supreme court of the fashion industry", so allowing the AI advert to run means they are "in some way ruling it as acceptable".
The BBC approached Vogue and Guess for comment. Vogue said it was an advert, not an editorial decision, but declined to respond further.
So, what does the future of the modelling industry look like?
Gonzalez and Petrescu believe that as their technology improves, they will be even more in demand by brands looking to do things differently.
Bovell thinks there will be more AI-generated models in the future, but "we aren't headed to a future where every model is created by AI".
She sees positives in the development of AI in the industry - predicting that anybody could "start to see ourselves as the fashion models" because we will be able to create a personal AI avatar to see how clothes look and fit.
However, she adds that we may get to the stage of "society opting out, and not being interested in AI models because it's so unattainable and we know it's not real".
More Weekend Picks
The procedures driving UK's cosmetic surgery rise
Women share their bittersweet experience after taking weight-loss drugs
Can LED face masks transform your skin? Here's what the experts say
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
The 3 Things That Matter for CRISPR Therapeutics Now
Key Points CRISPR Therapeutics' gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company has plenty of money right now, but its expenses could grow quite a bit from here. 10 stocks we like better than CRISPR Therapeutics › Biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion. The company remains in the red largely because it's barely got any revenue to speak of. It's not likely to swing to a profit in the immediate future, either. Still, if you've got room in your portfolio for a little more risk paired with above-average upside potential, this is a stock worth adding to your watchlist (if not your portfolio) with three key things in mind. But first things first. What's CRISPR Therapeutics? Although the company was founded back in 2013, most of its time since then has been spent refining the work first done by Jennifer Doudna, Ph.D., and co-founder Emmanuelle Charpentier, Ph.D., who jointly figured out how to "edit" defective genetic code in a strand of DNA. By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short palindromic repeats -- or CRISPR -- medical science is now able to do what was once unthinkable. It's still early days for the science -- very early. In fact, the FDA only made its first-ever approval of a gene-editing therapy in December of 2023. That's Casgevy, for the treatment of sickle cell disease, which was approved in the U.K. only a month earlier. The thing is, Casgevy is CRISPR Therapeutics' treatment, underscoring how well developed this biotech outfit's science is, and perhaps indirectly underscoring the fact that many rival drug developers are still well behind. Casgevy isn't the company's proverbial big Kahuna, however -- it's merely proof that gene editing can be successfully done. The heavy hitters in CRISPR's developmental pipeline are CTX310 for the treatment of certain cardiovascular diseases, and CTX131 and CTX112, both of which are taking aim at cancer using the very same CRISPR science. Although all of these drugs still have years of developmental work ahead of them, again, the underlying gene-editing technology works. Its potential applications are enormous. That's why CRISPR has a dozen or so others in clinical or pre-clinical trials also underway at this time. Three things to watch As time marches on, though, this stock's backstory is evolving from one broadly driven by an idea to one that increasingly hinges on some very specific factors. To this end, here are the three things that matter the most to current and prospective CRISPR Therapeutics shareholders right now -- and for the foreseeable future -- since they'll either drive the stock higher or let it slide into a sell-off. 1. Insurers and patients' acceptance of CRISPR-based medicine's cost While the science of using CRISPR to repair faulty cells is exciting, it's not exactly cheap or easy. See, Casgevy isn't a pill or an injection. It requires a sample of a patient's own blood stem cells to create a completely customized therapy, which is then infused back into that patient after he or she has undergone chemotherapy. All of this care can only be done at one of CRISPR's 65 authorized treatment centers. Total cost? A little over $2 million per patient. That's pretty steep for any therapy, but particularly for sickle cell disease, which at least has a handful of more affordable treatment options. The cost of treating life-threatening cancer is less of a stumbling block, even for insurers that may occasionally see bills nearly this size for even the most conventional of oncology treatment regimens. The price tag of this and any other future CRISPR-based therapy, however, is likely to remain in this ballpark, where payers may well balk. 2. The ongoing development of CTX310 Again, while Casgevy is approved to treat sickle cell disease, it's really more of a proving ground for the other drugs in CRISPR Therapeutics' developmental pipeline. This, of course, includes CTX131 and CTX112, but the company itself is putting the spotlight on CTX310 as a treatment for ANGPTL3 (angiopoietin-like 3), which is often associated with poorly regulated cholesterol, lipids, and triglycerides. If the company can demonstrate its solution is at least as good as (if not better than) alternative cholesterol-fighting drugs, investors might continue to support this stock. This information is coming. The company posted encouraging early results of CTX310's phase 1 clinical trial late last month, and says it intends to offer more detailed data at a healthcare conference scheduled for later in the year. If it's compelling enough, it could tamp down worries over the high cost of any CRISPR-based treatment. 3. Liquidity Finally, you'll want to keep an eye on CRISPR Therapeutics' liquidity, or the amount of cash it has on hand to cover its operating costs while it continues to develop CTX310 at the same time it's looking to expand Casgevy's commercialization. As of the end of the first quarter, CRISPR was sitting on $1.86 billion in cash, which is a lot for a company of this size. It's working through this money pretty quickly, though, shelling out nearly $150 million in operating expenses in Q1 alone. That doesn't include a full quarter's worth of the sort of costs the phase 1 trial of CTX310 is incurring now, or any other trials it starts or expands in the foreseeable future. Continued revenue growth from Casgevy should seemingly help offset some of this spending, even if not all of it. Indeed, the analyst community expects CRISPR's top line to soar from less than $50 million this year to more than $400 million in 2027, even if these same analysts believe the company will still be well in the red then. A few years' worth of losses isn't exactly unusual for a young biotech start-up. CRISPR Therapeutics would still lack much-needed scale even after such growth, though. The money it needs to spend just to get any meaningful degree of traction from Casgevy or maintain its clinical trials could far exceed any conceivable amount of revenue the newly approved drug might produce in the foreseeable future. Don't confuse what CRSP stock is So what's the call? There isn't one -- not this time. Buying or avoiding a stake in CRISPR Therapeutics is entirely up to you, depending on your risk tolerances and your ability to manage such a holding. If you're strictly a buy-and-hold investor, there's probably not enough certainty here yet to latch onto for the long haul. And there may never be. If you've got a speculative side that can tolerate risk in exchange for hype-driven reward, though, you could make a decent bullish case. Just don't confuse the two, or muddy the waters by trying to be both. The last thing you want to do here is talk yourself into a long-term position that requires you to ignore obvious red flags like the three potential ones discussed above. Should you buy stock in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy. The 3 Things That Matter for CRISPR Therapeutics Now was originally published by The Motley Fool
Yahoo
4 minutes ago
- Yahoo
‘Cleared for Takeoff': Truist Suggests 2 Aerospace Stocks to Buy Ahead of Earnings
Earnings season is in full swing, and investors are on the hunt for opportunities. One place where optimism is building – both on Wall Street and across the tarmac – is the aerospace sector. With commercial air travel rebounding and defense spending holding steady, several industry players appear well-positioned to deliver strong quarterly results. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Reinforcing this upbeat outlook, Truist analyst and aerospace expert Michael Ciarmoli believes investors should buckle up and prepare for takeoff. The analyst sees promising momentum in small- to mid-sized aerospace names ahead of their earnings reports. He highlights encouraging data points, such as year-over-year delivery increases from Boeing and Airbus – the world's leading aircraft manufacturers – as well as continued robust demand from the U.S. Department of Defense. 'Heading into 2Q25 earnings season we generally have a positive view of the demand backdrop across all A&D sub-sectors — comm'l aero aftermarket, comm'l aero OEM, and defense… We believe quarterly results will be solid and firmly anticipate that 2025 outlooks can be lifted. Our degree of confidence is highest in the aero aftermarket followed closely by aero OEM which seems poised to benefit from higher MAX and LEAP rates in the coming months,' Ciarmoli noted. With that setup, Ciarmoli has his eye on two small-cap aerospace stocks he believes are especially well-positioned heading into earnings. A quick scan through the TipRanks database shows that these are still flying under the radar, with Ciarmoli among the few analysts covering them. Let's dive in and see what makes these compelling choices. Astronics Corporation (ATRO) First up is Astronics, a $1.2 billion aerospace tech player that's been quietly powering the skies since 1968. Known for pushing the envelope on innovation, the company has carved out a strong niche in advanced support systems for commercial, business, and military aircraft. From cockpit lighting to power distribution and connectivity solutions, Astronics is embedded in the high-tech backbone of modern aviation. Its expertise shines, literally, in the cockpit, where it supplies lighting systems for instrument panels, as well as illumination for cabins and aircraft exteriors. The company also delivers integrated electrical power systems, including those tucked into passenger seating. Along with the lighting and power systems, Astronics provides products and solutions for connectivity and data systems, an increasingly important niche in the aircraft industry. Data systems allow aircraft cockpits to link with commercial and military applications; 'smart' sensing systems provide the information that data systems require; in-flight entertainment and connectivity are becoming ever more important for commercial carriers; and all of these are tied together by integrated engineering for turnkey solutions. Astronics backs up all its work with solutions for aircraft safety systems, ranging from onboard safety and survival kits to enhanced vision systems that allow flight crews to navigate in all conditions. Astronics works with customers across the civilian and military aviation sectors, and is known as a provider of unique or specialty technology products in various experimental aircraft programs. In a recent example, the company has been named as the supplier of the frequency converter unit for the NASA–Boeing X-66 experimental demonstrator airliner. We'll see Astronics' second-quarter results on August 6, but for now we can look back at the Q1 results. In the first quarter of this year, Astronics reported total sales revenue of $205.9 million. This was up more than 11% year-over-year, and it beat the forecast by $14 million. Sales in the key aerospace segment were up 17% y/y and hit a record level of $191.4 million. At the bottom line, Astronics had an EPS of $0.26, based on quarterly net income of $9.5 million. Looking ahead, Astronics finished the first quarter with a record-level work backlog of $673 million. Turning to Truist's Michael Ciarmoli, we find the analyst upbeat on this stock, noting that the company will see additional business as Boeing recovers from its own woes and increases production of the 737 MAX airliner series. 'We view ATRO as a beneficiary of ramping MAX production and see total MAX annual revenues tracking to 8-10% of total revenues in the 26/27 time period. We expect management will be in position to maintain its current 2025 revenue outlook of $820-$860M which contemplates potential downside pressures from tariffs and related uncertainty. While we have not made any changes to our model we believe we have seen enough tangible evidence in recent commercial aero bookings, top line revenue growth, and importantly aerospace segment margins that we believe this financial performance will continue for the remainder of 2025 and into 2026. With a higher degree of confidence in our margin and growth assumptions we believe ATRO's sharply discounted,' Ciarmoli opined. Ciarmoli puts a Buy rating on this stock, backing that with a $49 price target that indicates potential for a 42% upside in the coming months. (To watch Ciarmoli's track record, click here) You can file the stock firmly in the 'under the radar' camp, as Ciarmoli aside, there are currently no other analysts covering this name. (See ATRO stock forecast) TAT Technologies (TATT) The second Truist pick we're looking at is TAT Technologies, a smaller player with a $420 million market cap. TAT has a global footprint, and is a provider of critical systems like thermal controls, APUs, and landing gear for a wide range of aircraft platforms. Among TAT's key product lines are its thermal solutions. This is a vital area for aircraft technology; at high speeds and altitudes, aircraft encounter extremes of both heat and cold. TAT's industry-leading thermal solutions include high-temperature-resistant precoolers, fuel-submerged hydraulic heat exchangers, oil coolers, advanced cold plates, air cycle and vapor cycle ECS heat exchangers, power electronics cooling systems, and environmental control systems. These systems regulate temperature across the aircraft, from the fuel system to passenger accommodations. Also vital to the industry is TAT's expertise in APU MRO – the maintenance, repair, and overhaul of auxiliary power units. These APUs are found in most aircraft, and are used to provide power for systems other than propulsion. In commercial airliners, the APU is usually located in the tailcone and is used to provide power for cabin electricity and lighting, and for the aircraft's communication systems. TAT is also a leading provider of MRO facility for Embraer landing gear. Embraer is one of the world's largest makers of commercial airliners, after Airbus and Boeing, and specializes in medium-haul, narrow-body jets. TAT's expertise in Embraer landing gear systems is in high demand. The company also operates at the leading edge of aerospace technology. TAT is involved in eVTOL projects – electric vertical take-off and landing – a new tech that promises to bring a sea-change to short-range and urban air transport. Closely linked to this is TAT's work with hybrid electric aircraft and universal cooling systems. So, TAT has its fingers in many areas of the aerospace realm. That brought the company $42.1 million in revenue during 1Q25, a total that was up 23% from the prior-year period although it missed the forecast by $452,000. TAT's bottom line in the quarter came to 34 cents per share, beating expectations by 4 cents per share. For Ciarmoli, the future looks bright for this aerospace firm. The analyst notes a strong market for APU expertise, and writes of TATT, 'We expect favorable aftermarket trends coupled with recent APU share gains to continue to drive revenue growth. We model for 22% YOY growth in 2Q25 and 6 % seq'l growth. We would expect to see gross margins expand YOY on volume/mix and operating efficiencies and we anticipate a B2B >1x. Following the equity offering at the end of May we will look for updates from mgmt regarding use of proceeds and suspect some near term build of working capital to support the narrow body APU opportunity.' These comments support the analyst's Buy rating on TATT shares, and his $35 price target suggests a 9% upside potential in the next 12 months. While there are only 3 recent analyst reviews on record for TATT, they are all Buys, giving the stock its Strong Buy consensus rating. The shares have a current trading price of $32 and an average target price of $36 points toward a one-year gain of 12%. (See TATT stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Corsair's Elgato Launches Facecam 4K; Groundbreaking Solution Mainstreams 4K60 Video
MILPITAS, Calif., July 29, 2025--(BUSINESS WIRE)--CORSAIR® (Nasdaq: CRSR) subsidiary Elgato, a global leader in content creator technology, today launched Facecam 4K, a groundbreaking studio webcam that brings DSLR-level 4K60 video to mainstream creators. Designed with a professional imaging pipeline, including a SONY STARVIS 2 sensor, advanced image processor, and Elgato's Camera Hub software, Facecam 4K delivers ultra-smooth, uncompressed Ultra HD footage with cinematic flexibility. It's also the first webcam to support 49-mm lens filters, enabling popular pro-style effects like starbursts and diffusion. Facecam 4K is available now, representing a major innovative leap in webcam technology, making broadcast-quality video and professional creative control more accessible than ever. With results rivaling many professional cameras, Facecam 4K proves that incredible video no longer requires a prohibitively expensive setup. Thi La, Chief Executive Officer of Corsair, said, "Facecam 4K is a great example of how Elgato continues to lead in creator technology, delivering pro-level 4K60 quality without the usual cost or complexity. As the creator economy evolves, we see opportunities to expand what a streaming webcam can do, especially through software, filters, and deeper app integrations. We're excited to give creators the tools they need to enhance their brand image, and this is just one step in our broader plan to drive further innovation." Customers can order Facecam 4K starting today on and at authorized retailers in CORSAIR's global network. Webpages Learn more about Facecam 4K: Get high-resolution product images: Get the Camera Hub app: About Elgato Elgato is a world leader in online audiovisual technology, empowering content creators and digital professionals to transform their ideas into immersive, impactful experiences. From award-winning cameras, microphones, and lighting to control surfaces, capture cards, and studio mounts, Elgato sets industry benchmarks that shape the status quo of digital storytelling. Backed by parent company CORSAIR (Nasdaq: CRSR), the brand leverages a strong global distribution network and consistent product innovation to deliver sustained growth. A trusted name in a rapidly expanding market, Elgato drives value for both creators and investors through its commitment to excellence and forward-thinking strategy. About Corsair Gaming Corsair (Nasdaq: CRSR) is a leading global developer and manufacturer of high-performance products and technology for gamers, content creators, and PC enthusiasts. From award-winning PC components and peripherals to premium streaming equipment and smart ambient lighting, Corsair delivers a full ecosystem of products that work together to enable everyone, from casual gamers to committed professionals, to perform at their very best. Corsair also sells products under its Fanatec brand, the leading end-to-end premium Sim Racing product line; Elgato brand, which provides premium studio equipment and accessories for content creators; SCUF Gaming brand, which builds custom-designed controllers for competitive gamers; Drop, the leading community-driven mechanical keyboard brand; and ORIGIN PC brand, a builder of custom gaming and workstation desktop PCs. Forward-Looking Statements This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the refinancing supporting the Company's growth plan and providing it flexibility to act on growth investments. Forward-looking statements are based on our management's beliefs, as well as assumptions made by, and information currently available to them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to: the Company's limited operating history, which makes it difficult to forecast the Company's future results of operations; current macroeconomic conditions, including the impacts of high inflation and risk of recession, on demand for our products, consumer confidence and financial markets generally; changes in trade regulations, policies, and agreements and the imposition of tariffs that affect our products or operations, including potential new tariffs that may be imposed on U.S. imports and our ability to mitigate; the Company's ability to build and maintain the strength of the Company's brand among gaming and streaming enthusiasts and ability to continuously develop and successfully market new products and improvements to existing products; the introduction and success of new third-party high-performance computer hardware, particularly graphics processing units and central processing units as well as sophisticated new video games; fluctuations in operating results; the loss or inability to attract and retain key management; the impacts from geopolitical events and unrest; delays or disruptions at the Company or third-parties' manufacturing and distribution facilities; and the other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") and our subsequent filings with the SEC. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. View source version on Contacts Investor Relations Contact: David Pasqualeir@ 914-337-8801 Media Contact: Timothy Bibatbiba@ 203-428-3222 Error in retrieving data Sign in to access your portfolio Error in retrieving data